Stock Research: AstraZeneca

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

AstraZeneca

LSE:AZN GB0009895292
28
  • Value
    10
  • Growth
    67
  • Safety
    Safety
    36
  • Combined
    12
  • Sentiment
    74
  • 360° View
    360° View
    28
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and commercializes prescription medicines. It operates in oncology, rare diseases, and biopharmaceuticals. In the last fiscal year, the company had a market cap of $216,842 million, profits of $44,415 million, revenue of $54,073 million, and 94,300 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 28 (better than 28% compared with alternatives), overall professional sentiment and financial characteristics for the stock AstraZeneca are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for AstraZeneca. The consolidated Growth Rank has a good rank of 67, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 67% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 74, which means that professional investors are more optimistic about the stock than for 74% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 36, which means that the share price of AstraZeneca is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 64% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 10, which means that the company has a financing structure that is riskier than those of 90% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
FTSE All Shares
FTSE 100
FTSE 350
Employee Focus EU
Diversity Europe
Human Rights
Renewables Users
NASDAQ
OMX 30
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 16-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
36 46 43 60
Growth
67 48 73 81
Safety
Safety
10 7 10 47
Sentiment
74 45 88 90
360° View
360° View
28 23 53 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
78 69 78 67
Opinions Change
43 19 52 52
Pro Holdings
n/a 87 92 80
Market Pulse
42 35 35 59
Sentiment
74 45 88 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
36 46 43 60
Growth
67 48 73 81
Safety Safety
10 7 10 47
Combined
12 15 28 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
52 51 51 58
Price vs. Earnings (P/E)
24 26 28 44
Price vs. Book (P/B)
10 18 15 34
Dividend Yield
69 71 74 70
Value
36 46 43 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
43 55 67 76
Profit Growth
65 42 60 74
Capital Growth
82 37 64 53
Stock Returns
59 67 42 68
Growth
67 48 73 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
18 20 20 9
Refinancing
7 6 7 96
Liquidity
42 54 44 32
Safety Safety
10 7 10 47

Similar Stocks

Discover high‑ranked alternatives to AstraZeneca and broaden your portfolio horizons.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Vodafone

LSE:VOD
Country: United Kingdom
Industry: Wireless Telecommunication
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.